BridgeBio Oncology Therapeutics, Inc.
BBOTBridgeBio Oncology Therapeutics, Inc. in brief
BridgeBio Oncology Therapeutics, Inc. is a listed company in the Biotechnology industry, based in South San Francisco, California, USA. Its market value was $217 M on 30 October 2026, which makes it the 15,960th largest listed company in the world and the 3,106th largest in the USA on this site. It employs about 92 people. Its shares trade under the symbol BBOT (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About BridgeBio Oncology Therapeutics, Inc.
BBOT is a clinical-stage biotechnology company with the mission of transforming the lives of patients with cancers driven by RAS and PI3Kα, the two most frequently mutated oncogenes. Aberrant RAS signaling drives uncontrolled tumor growth in some of the deadliest cancers, including lung, breast, pancreas and colon cancer. This can come from mutations in RAS itself, which underlie approximately 30% of all human cancers, or from RAS-mediated overactivation of PI3Kα. Our goal is to provide meaningful benefit to patients by designing and developing new therapies to achieve high levels of target inhibition against these oncogenic drivers while maintaining a favorable tolerability profile.
From the company's annual report filed with the US SEC: read the report
BridgeBio Oncology Therapeutics, Inc. timeline
- 2023
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2024
- 🔔Initial public offering as Helix Acquisition Corp. IIFinal prospectus filed with the SEC on 13 February 2024; shares registered for exchange trading on 8 February 2024. The blank-check company later merged with the business that carries the name today.
- 2025
- ✎Renamed BridgeBio Oncology Therapeutics, Inc.Formerly Helix Acquisition Corp. II.
Events of BridgeBio Oncology Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
Not enough history yet.
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 0.5×
- Free cash flow yield
- -52.8%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -32.6%
- Liabilities / assets
- 8.3%
- Profit per employee
- $-1.5 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-146M | $-134M | — |
| Dec 2024 | — | — | $-81M | $-74M | — |
| Dec 2023 | — | — | $-0M | $-0M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-114M | $1M | $-115M | $-4.30 | — |
| Dec 2024 | $-55M | $0M | $-55M | $-5756.41 | — |
| Dec 2023 | — | — | — | — | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-34M. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Nov 5, 20268-KCurrent reportDirectors or officers changed
- Sep 8, 20268-KCurrent reportOther events
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Aug 11, 20268-KCurrent reportResults of operations
- Jun 22, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- May 12, 202610-QQuarterly report · period to Mar 2026
- May 12, 20268-KCurrent reportResults of operations
- Apr 29, 20268-KCurrent reportDirectors or officers changed
- Apr 28, 2026DEF 14AProxy statement
- Apr 23, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
Official filings of BridgeBio Oncology Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-146 M
- Net income
- $-134 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $448 M
- Total liabilities
- $37 M
- Total equity
- $411 M
As of December-2025
Top 89 institutional investors in BridgeBio Oncology Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Cormorant Asset Management, LP | 17,878,594 | 0 (0.00%) | 22.28% | $73 M | Nov 16, 2026 |
| 2 | BlackRock, Inc. | 4,009,791 | +1,855,751 (+86.15%) | 5.00% | $16 M | Nov 13, 2026 |
| 3 | Omega Fund Management, LLC | 3,289,661 | 0 (0.00%) | 4.10% | $13 M | Nov 16, 2026 |
| 4 | Deerfield Management Company, L.P. | 3,138,167 | -1,747,279 (-35.76%) | 3.91% | $13 M | Nov 16, 2026 |
| 5 | Alphabet Inc. | 2,823,126 | 0 (0.00%) | 3.52% | $12 M | Nov 6, 2026 |
| 6 | Citadel Advisors LLC | 2,697,077 | +79,250 (+3.03%) | 3.36% | $11 M | Nov 16, 2026 |
| 7 | Enavate Sciences GP, LLC | 2,626,946 | 0 (0.00%) | 3.27% | $11 M | Nov 16, 2026 |
| 8 | Regents Of The University Of California | 2,509,446 | New | 3.13% | $10 M | Oct 26, 2026 |
| 9 | Armistice Capital, LLC | 2,264,000 | +500,000 (+28.34%) | 2.82% | $9 M | Nov 16, 2026 |
| 10 | Novo Holdings A/s | 2,250,000 | 0 (0.00%) | 2.80% | $9 M | Nov 16, 2026 |
| 11 | Laurion Capital Management LP | 2,002,701 | 0 (0.00%) | 2.50% | $8 M | Oct 30, 2026 |
| 12 | Vanguard Capital Management LLC | 1,991,016 | -14,633 (-0.73%) | 2.48% | $8 M | Nov 13, 2026 |
| 13 | Wellington Management Group LLP | 1,430,687 | -1,358,615 (-48.71%) | 1.78% | $6 M | Nov 16, 2026 |
| 14 | Aisling Capital Management LP | 1,018,018 | 0 (0.00%) | 1.27% | $4 M | Nov 12, 2026 |
| 15 | State Street Corp | 893,262 | -143,307 (-13.83%) | 1.11% | $4 M | Nov 12, 2026 |
| 16 | EcoR1 Capital, LLC | 889,607 | -1,933,519 (-68.49%) | 1.11% | $4 M | Nov 16, 2026 |
| 17 | Catalio Capital Management, LP | 699,532 | +381,125 (+119.70%) | 0.87% | $3 M | Nov 16, 2026 |
| 18 | Opaleye Management Inc. | 630,000 | -70,000 (-10.00%) | 0.79% | $3 M | Nov 16, 2026 |
| 19 | Geode Capital Management, LLC | 556,989 | -65,362 (-10.50%) | 0.69% | $2 M | Nov 6, 2026 |
| 20 | Marshall Wace, LLP | 482,935 | New | 0.60% | $2 M | Nov 13, 2026 |
| 21 | Sphera Funds Management LTD. | 464,480 | +3,495 (+0.76%) | 0.58% | $2 M | Nov 16, 2026 |
| 22 | Granahan Investment Management, LLC | 437,004 | -121,522 (-21.76%) | 0.54% | $2 M | Nov 16, 2026 |
| 23 | Adage Capital Partners GP, L.L.C. | 400,000 | 0 (0.00%) | 0.50% | $2 M | Nov 16, 2026 |
| 24 | BNP Paribas Financial Markets | 349,576 | +158,424 (+82.88%) | 0.44% | $1 M | Nov 12, 2026 |
| 25 | Price T Rowe Associates Inc /MD/ | 298,798 | -1,202 (-0.40%) | 0.37% | $1 M | Nov 16, 2026 |
Show all 89: investors 26 to 89
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Qube Research & Technologies Ltd | 290,548 | New | 0.36% | $1 M | Nov 13, 2026 |
| 27 | Charles Schwab Investment Management Inc | 285,709 | -809 (-0.28%) | 0.36% | $1 M | Nov 16, 2026 |
| 28 | Casdin Capital, LLC | 282,312 | 0 (0.00%) | 0.35% | $1 M | Nov 16, 2026 |
| 29 | DAFNA Capital Management LLC | 266,038 | New | 0.33% | $1 M | Nov 16, 2026 |
| 30 | Vanguard Fiduciary Trust Co | 264,427 | -27,095 (-9.29%) | 0.33% | $1 M | Nov 13, 2026 |
| 31 | Goldman Sachs Group Inc | 239,614 | +137,529 (+134.72%) | 0.30% | $1 M | Nov 16, 2026 |
| 32 | Ensign Peak Advisors, Inc | 228,620 | -44,910 (-16.42%) | 0.28% | $1 M | Nov 12, 2026 |
| 33 | Brevan Howard Capital Management LP | 165,133 | +76,238 (+85.76%) | 0.21% | $1 M | Nov 16, 2026 |
| 34 | Squarepoint Ops LLC | 156,980 | +137,318 (+698.39%) | 0.20% | $1 M | Nov 9, 2026 |
| 35 | Millennium Management LLC | 144,430 | +38,950 (+36.93%) | 0.18% | $1 M | Nov 16, 2026 |
| 36 | Victory Capital Management Inc | 128,563 | New | 0.16% | $1 M | Nov 10, 2026 |
| 37 | Moore Capital Management, LP | 100,000 | 0 (0.00%) | 0.12% | $0 M | Nov 16, 2026 |
| 38 | Tidal Investments LLC | 99,750 | +6,411 (+6.87%) | 0.12% | $0 M | Nov 13, 2026 |
| 39 | Tema Etfs LLC | 99,750 | +6,411 (+6.87%) | 0.12% | $0 M | Oct 16, 2026 |
| 40 | Palumbo Wealth Management LLC | 95,443 | +9,819 (+11.47%) | 0.12% | $0 M | Nov 13, 2026 |
| 41 | Royal Bank Of Canada | 82,439 | New | 0.10% | $0 M | Nov 16, 2026 |
| 42 | Schonfeld Strategic Advisors LLC | 67,861 | +56,357 (+489.89%) | 0.08% | $0 M | Nov 16, 2026 |
| 43 | Renaissance Technologies LLC | 64,000 | +5,400 (+9.22%) | 0.08% | $0 M | Nov 12, 2026 |
| 44 | ExodusPoint Capital Management, LP | 60,597 | New | 0.08% | $0 M | Nov 16, 2026 |
| 45 | EntryPoint Capital, LLC | 54,756 | New | 0.07% | $0 M | Nov 13, 2026 |
| 46 | Axq Capital, LP | 53,001 | +42,273 (+394.04%) | 0.07% | $0 M | Nov 12, 2026 |
| 47 | Dimensional Fund Advisors LP | 52,406 | New | 0.07% | $0 M | Nov 4, 2026 |
| 48 | Bank Of America Corp /de/ | 50,816 | -26,324 (-34.12%) | 0.06% | $0 M | Nov 16, 2026 |
| 49 | Fox Run Management, L.L.C. | 50,778 | New | 0.06% | $0 M | Nov 12, 2026 |
| 50 | Susquehanna Portfolio Strategies, LLC | 48,230 | New | 0.06% | $0 M | Nov 16, 2026 |
| 51 | TD Asset Management Inc | 42,730 | 0 (0.00%) | 0.05% | $0 M | Nov 13, 2026 |
| 52 | Virtus Investment Advisers, LLC | 40,946 | -1,274 (-3.02%) | 0.05% | $0 M | Nov 12, 2026 |
| 53 | Morgan Stanley | 38,899 | +35,519 (+1050.86%) | 0.05% | $0 M | Nov 13, 2026 |
| 54 | Y-Intercept (Hong Kong) Ltd | 38,846 | New | 0.05% | $0 M | Oct 16, 2026 |
| 55 | Canada Pension Plan Investment Board | 38,300 | New | 0.05% | $0 M | Nov 16, 2026 |
| 56 | XTX Topco Ltd | 37,065 | New | 0.05% | $0 M | Nov 16, 2026 |
| 57 | Ameriprise Financial Inc | 35,907 | New | 0.04% | $0 M | Nov 16, 2026 |
| 58 | UBS Group AG | 31,825 | -82,830 (-72.24%) | 0.04% | $0 M | Nov 10, 2026 |
| 59 | Catalyst Funds Management Pty Ltd | 30,601 | New | 0.04% | $0 M | Nov 12, 2026 |
| 60 | Mercer Global Advisors Inc /adv | 30,000 | New | 0.04% | $0 M | Nov 16, 2026 |
| 61 | Point72 Asset Management, L.P. | 29,570 | New | 0.04% | $0 M | Nov 16, 2026 |
| 62 | Rafferty Asset Management, LLC | 28,581 | +5,975 (+26.43%) | 0.04% | $0 M | Nov 13, 2026 |
| 63 | Manufacturers Life Insurance Company, The | 28,016 | +32 (+0.11%) | 0.03% | $0 M | Nov 13, 2026 |
| 64 | Jump Financial, LLC | 26,775 | -35,225 (-56.81%) | 0.03% | $0 M | Nov 13, 2026 |
| 65 | Trexquant Investment LP | 26,360 | New | 0.03% | $0 M | Nov 16, 2026 |
| 66 | Northern Trust Corp | 25,000 | -161,482 (-86.59%) | 0.03% | $0 M | Nov 16, 2026 |
| 67 | CIBC Bancorp USA Inc. | 25,000 | New | 0.03% | $0 M | Nov 13, 2026 |
| 68 | FMR LLC | 24,479 | -216,108 (-89.83%) | 0.03% | $0 M | Nov 10, 2026 |
| 69 | Aster Capital Management (DIFC) Ltd | 21,220 | New | 0.03% | $0 M | Nov 12, 2026 |
| 70 | Virtu Financial LLC | 20,926 | New | 0.03% | $0 M | Nov 17, 2026 |
| 71 | PDT Partners, LLC | 20,801 | New | 0.03% | $0 M | Nov 16, 2026 |
| 72 | Barclays PLC | 19,924 | +17,825 (+849.21%) | 0.02% | $0 M | Nov 6, 2026 |
| 73 | Jain Global LLC | 18,535 | New | 0.02% | $0 M | Nov 16, 2026 |
| 74 | Vanguard Global Advisers, LLC | 18,163 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 75 | ADAR1 Capital Management, LLC | 17,183 | New | 0.02% | $0 M | Nov 16, 2026 |
| 76 | Gsa Capital Partners LLP | 16,608 | New | 0.02% | $0 M | Nov 16, 2026 |
| 77 | China Universal Asset Management Co., Ltd. | 16,000 | New | 0.02% | $0 M | Oct 28, 2026 |
| 78 | Hudson Bay Capital Management LP | 13,742 | New | 0.02% | $0 M | Nov 13, 2026 |
| 79 | Prelude Capital Management, LLC | 13,124 | New | 0.02% | $0 M | Nov 16, 2026 |
| 80 | HSBC Holdings PLC | 12,259 | New | 0.02% | $0 M | Nov 16, 2026 |
| 81 | Citigroup Inc | 10,875 | -8,997 (-45.27%) | 0.01% | $0 M | Nov 4, 2026 |
| 82 | Tower Research Capital LLC (TRC) | 4,367 | +2,671 (+157.49%) | 0.01% | $0 M | Nov 16, 2026 |
| 83 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 2,212 | -414 (-15.77%) | 0.00% | $0 M | Nov 16, 2026 |
| 84 | Rockefeller Capital Management L.P. | 2,000 | +1,000 (+100.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 85 | Quarry LP | 1,696 | +1,499 (+760.91%) | 0.00% | $0 M | Nov 16, 2026 |
| 86 | Toth Financial Advisory Corp | 1,600 | New | 0.00% | $0 M | Oct 8, 2026 |
| 87 | Nuveen, LLC | 960 | New | 0.00% | $0 M | Nov 10, 2026 |
| 88 | Wells Fargo & Company/mn | 300 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 89 | SBI Securities Co., Ltd. | 187 | New | 0.00% | $0 M | Oct 22, 2026 |
Mutual funds holding BridgeBio Oncology Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.42 M | $11 M | 1.8% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc. | 813,301 | $6 M | 1.0% | 0.06% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Health Sciences Opportunities PortfolioBlackRock Advisors, LLC | 673,766 | $6 M | 0.84% | 0.10% | no change | May 29, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 539,581 | $4 M | 0.67% | <0.01% | +0.3% | Jun 30, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 306,024 | $2 M | 0.38% | 0.03% | −5.7% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 250,892 | $2 M | 0.31% | <0.01% | −0.7% | May 31, 2026 |
| 🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC | 240,300 | $2 M | 0.30% | 0.04% | no change | May 31, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 227,258 | $2 M | 0.28% | <0.01% | −1.5% | May 31, 2026 |
| 🇺🇸 BlackRock Health Sciences Term TrustBlackRock Advisors, LLC | 263,669 | $2 M | 0.33% | 0.19% | no change | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc. | 222,512 | $2 M | 0.28% | 0.01% | −33% | Jun 30, 2026 |
| 🇺🇸 Royce Micro-Cap Trust, Inc.Royce & Associates, LP | 210,854 | $2 M | 0.26% | 0.18% | +42% | Jun 30, 2026 |
| 🇺🇸 Victory Small Cap Stock FundVictory Capital Management Inc. | 134,743 | $1 M | 0.17% | 0.11% | +62% | Jul 31, 2026 |
| 🇺🇸 Tema Oncology ETFTema ETFs LLC | 93,339 | $1 M | 0.12% | 0.48% | new | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 90,376 | $1 M | 0.11% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Royce Micro-Cap FundRoyce & Associates, LP | 87,617 | $1 M | 0.11% | 0.16% | +27% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 72,932 | $1 M | 0.09% | <0.01% | +4.8% | May 31, 2026 |
| 🇺🇸 BlackRock Health Sciences TrustBlackRock Advisors, LLC | 60,030 | $0 M | 0.07% | 0.08% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 49,459 | $0 M | 0.06% | <0.01% | +2.3% | May 31, 2026 |
| 🇺🇸 Royce Small-Cap Trust, Inc.Royce & Associates, LP | 44,789 | $0 M | 0.06% | 0.01% | −79% | Jun 30, 2026 |
| 🇺🇸 Health Sciences PortfolioPacific Life Fund Advisors LLC | 40,663 | $0 M | 0.05% | 0.08% | no change | Jun 30, 2026 |
| 🇺🇸 Royce Small-Cap FundRoyce & Associates, LP | 38,053 | $0 M | 0.05% | 0.01% | −79% | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 32,000 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc. | 27,500 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC | 27,634 | $0 M | 0.03% | 0.05% | new | Jul 31, 2026 |
| 🇺🇸 Royce Capital Fund - Micro-Cap PortfolioRoyce & Associates, LP | 28,976 | $0 M | 0.04% | 0.16% | — | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 28,792 | $0 M | 0.04% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 24,941 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Acuitas US Microcap FundAcuitas Investments, LLC | 24,350 | $0 M | 0.03% | 0.16% | — | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 18,529 | $0 M | 0.02% | <0.01% | +11% | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc. | 15,774 | $0 M | 0.02% | 0.02% | −26% | Jun 30, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 15,579 | $0 M | 0.02% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 7,506 | $0 M | <0.01% | 0.01% | +3.6% | Jul 31, 2026 |
| 🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC | 7,262 | $0 M | <0.01% | 0.02% | −26% | Jun 30, 2026 |
| 🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC | 4,884 | $0 M | <0.01% | 0.02% | −26% | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 4,825 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 4,161 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 3,155 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 1,414 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 1,180 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 39 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at BridgeBio Oncology Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Marc CoboPrincipal Accounting Officer | Sell10b5-1 plan | -78 | $2.370 | $185 | 13,734 | Form 4 |
| filed | Marc CoboPrincipal Accounting Officer | Shares withheld for tax | -203 | $2.680 | $544 | 13,812 | Form 4 |
| filed | Pedro BeltranPresident and CEO, Director | Shares withheld for tax | -1,047 | $3.940 | $4 K | 43,529 | Form 4 |
| filed | Marc CoboPrincipal Accounting Officer | Shares withheld for tax | -126 | $3.940 | $496 | 14,015 | Form 4 |
| filed | Idan ElmelechCOO & Principal Financial Ofcr | Shares withheld for tax | -343 | $3.940 | $1 K | 14,152 | Form 4 |
| filed | Yong BenChief Med & Dev Officer | Shares withheld for tax | -1,047 | $3.940 | $4 K | 43,529 | Form 4 |
| filed | Marc CoboPrincipal Accounting Officer | Grant or award | +9,038 | — | — | 14,344 | Form 4 |
| filed | Marc CoboPrincipal Accounting Officer | Shares withheld for tax | -203 | $5.520 | $1 K | 14,141 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: BridgeBio Oncology Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 4,420 shares at $2.70
- : 1 shares at $10.23
- : 171,200 shares at $2.72
- : 105,672 shares at $10.32
- : 2,988 shares at $3.94
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
BridgeBio Oncology Therapeutics, Inc. scorecard#
Passes 2 of the 8 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.5×Price to book 0.5× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-52.8%Free cash flow is -52.8% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-4.30 vs -5756.41Diluted EPS -4.30 in fiscal 2025 against -5756.41 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$134 MNet income -$134 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-115.3%-115.3% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 1
- ✓Short-term assets cover short-term liabilities12.3×Current ratio 12.34 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
BridgeBio Oncology Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 |
|---|---|---|---|---|
| Income statement | ||||
| Research and development | 121+65.8%— | 73—— | — | |
| General and administrative | 25+217%— | 7.8r0.6+18503%— | 0.0—— | |
| Operating expenses | 146+80.3%— | 81—— | — | |
| Operating income | −146—— | −81r−0.6—— | −0.0—— | |
| Interest and finance income | — | 8.4—— | — | |
| Other non-operating income (expense) | 12+78.7%— | 6.6r8.2—— | — | |
| Income tax | 0—— | 0—— | — | |
| Net income attributable to shareholders | −134—— | −74r7.6—— | −0.0—— | |
| Earnings per share, basic | -4.30—— | -5,756.41—— | — | |
| Earnings per share, diluted | -4.30—— | -5,756.41—— | — | |
| Shares, weighted average (basic) | 31+241276%— | 0.0—— | — | |
| Shares, weighted average (diluted) | 31+241276%— | 0.0—— | — | |
| Balance sheet | ||||
| Cash and cash equivalents | 374+1111%83.3% | 31—18.8% | 0—0.0% | |
| Short-term investments | 52−58.5%11.5% | 125—75.9% | — | |
| Other current assets | 6.6+120%1.5% | 3.0r0.0—1.8% | — | |
| Current assets | 432+172%96.4% | 159r1.9—96.6% | — | |
| Property, plant and equipment | 1.0+95.1%0.2% | 0.5—0.3% | — | |
| Right-of-use (leased) assets | 2.3—0.5% | 0—0.0% | — | |
| Total assets | 448+173%100% | 164r194+49255%100% | 0.3—100% | |
| Accounts payable | 1.4−55.3%0.3% | 3.1r0.1—1.9% | — | |
| Current liabilities | 35+79.0%7.8% | 20r0.2+4839%11.9% | 0.4—119% | |
| Lease liabilities (non-current) | 2.2—0.5% | 0—0.0% | — | |
| Total liabilities | 37+90.4%8.3% | 20r5.7+4839%11.9% | 0.4—119% | |
| Retained earnings | −357—−79.5% | −223r−3.7—−135% | −0.1—−26.6% | |
| Shareholders' equity | 411—91.7% | −179r−3.7—−109% | −116r−0.1—−34738% | |
| Total liabilities and equity | 448+173%100% | 164r194+49255%100% | 0.3—100% | |
| Shares outstanding | 80+281412%— | 0.0—— | — | |
| Cash-flow statement | ||||
| Share-based compensation | 5.9+32.7%— | 4.4r0.3—— | — | |
| Cash from operating activities | −114—— | −55r−0.8—— | — | |
| Capital expenditure | −0.6—— | −0.0—— | — | |
| Cash from investing activities | 73—— | −121r−184—— | — | |
| Shares issued | 112—— | — | — | |
| Cash from financing activities | 383+85.9%— | 206r186—— | — | |
| Report | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||
| Research and development | 157+52.6%— | 30−15.6%— | 49+79.4%— | 40+92.9%— | 38*+94.9%— | 35+95.9%— | 27—— | 21—— | 20*—— | 18—— | — | — | |
| General and administrative | 31+41.4%— | 7.9−44.1%— | 11+313%— | 6.4+155%— | 5.3*+128%— | 14+696%— | 2.7r1.1+1643%— | 2.5r2.4+3651%— | 2.3r0.2*—— | 1.8r0.1—— | 0.2—— | 0.1—— | |
| Operating expenses | 187+50.7%— | 37−23.8%— | 60+100%— | 46+99.6%— | 43*+98.4%— | 49+150%— | 30—— | 23—— | 22*—— | 20—— | — | — | |
| Operating income | −187—— | −37—— | −60—— | −46—— | −43*—— | −49—— | −30r−1.1—— | −23r−2.4—— | −22r−0.2*—— | −20r−0.1—— | −0.2—— | −0.1—— | |
| Interest and finance income | — | — | — | — | — | — | 2.1−15.0%— | 2.0+64.9%— | 2.2*—— | 2.6—— | 2.4—— | 1.2—— | |
| Other non-operating income (expense) | 16+68.1%— | 3.3−25.1%— | 3.7+125%— | 4.1+276%— | 4.6*+110%— | 4.4+89.0%— | 1.7r2.0−29.9%— | 1.1r1.9−7.3%— | 2.2r2.2*—— | 2.3r2.5—— | 2.4—— | 1.2—— | |
| Income tax | — | 0—— | 0—— | — | 0*—— | 0—— | 0—— | 0—— | 0*—— | 0—— | — | — | |
| Net income attributable to shareholders | −172—— | −34—— | −56—— | −42—— | −39*—— | −45—— | −28r0.9—— | −22r−0.5—— | −20r2.0*—— | −17r2.3—— | −22r2.2—— | −15r1.1—— | |
| Earnings per share, basic | — | -0.43—— | -705.20—— | -526.11—— | — | -1.03—— | -566.46—— | -54.23—— | — | -1,562.18—— | — | — | |
| Earnings per share, diluted | — | -0.43—— | -705.20—— | -526.11—— | — | -1.03—— | -566.46—— | -54.23—— | — | -1,562.18—— | — | — | |
| Shares, weighted average (basic) | 80+84.4%— | 80+84.4%— | 80+59.5%— | 0.1−80.3%— | — | 43+392100%— | 50—— | 0.4—— | — | 0.0—— | — | — | |
| Shares, weighted average (diluted) | 80+84.4%— | 80+84.4%— | 80+59.5%— | 0.1−80.3%— | — | 43+392100%— | 50—— | 0.4—— | — | 0.0—— | — | — | |
| Balance sheet | |||||||||||||
| Cash and cash equivalents | 76—22.1% | 76−81.3%22.1% | 54+8039%14.4% | 53+5367%12.6% | 374+1111%83.3% | 409+22790%84.3% | 0.7−63.4%0.3% | 1.0−47.8%0.5% | 31—18.8% | 1.8—0.9% | 1.8—1.0% | 1.8—1.0% | |
| Short-term investments | 117—33.9% | 117+97.1%33.9% | 172—45.6% | 200—47.8% | 52−58.5%11.5% | 60—12.3% | — | — | 125—75.9% | — | — | — | |
| Other current assets | 14—4.1% | 14+90.7%4.1% | 16+25510%4.2% | 14—3.4% | 6.6+120%1.5% | 7.5—1.5% | 0.1—0.0% | — | 3.0r0.0—1.8% | — | — | — | |
| Current assets | 208—60.2% | 208−56.2%60.2% | 242+27544%64.3% | 267+21403%63.8% | 432+172%96.4% | 476+23213%98.2% | 0.9−57.8%0.4% | 1.2−41.3%0.6% | 159r1.9—96.6% | 2.0—1.1% | 2.1—1.1% | 2.1—1.1% | |
| Property, plant and equipment | 0.8—0.2% | 0.8−1.5%0.2% | 0.9—0.2% | 0.9—0.2% | 1.0+95.1%0.2% | 0.8—0.2% | — | — | 0.5—0.3% | — | — | — | |
| Right-of-use (leased) assets | 2.0—0.6% | 2.0−18.6%0.6% | 2.1—0.6% | 2.2—0.5% | 2.3—0.5% | 2.4—0.5% | — | — | 0—0.0% | — | — | — | |
| Total assets | 346—100% | 346−28.6%100% | 377+90.8%100% | 418+113%100% | 448+173%100% | 485+152%100% | 197+4.0%100% | 196+4.3%100% | 164r194—100% | 192—100% | 190—100% | 188—100% | |
| Accounts payable | 10—3.0% | 10+181%3.0% | 6.7+167%1.8% | 12—2.9% | 1.4−55.3%0.3% | 3.7—0.8% | 2.5—1.3% | — | 3.1r0.1—1.9% | — | — | — | |
| Current liabilities | 51—14.7% | 51+42.9%14.7% | 52+1864%13.7% | 43+2212%10.4% | 35+79.0%7.8% | 36+28088%7.4% | 2.6+3222%1.3% | 1.9+7918%1.0% | 20r0.2—11.9% | 0.1—0.1% | 0.1—0.0% | 0.0—0.0% | |
| Lease liabilities (non-current) | 1.8—0.5% | 1.8−24.0%0.5% | 2.0—0.5% | 2.1—0.5% | 2.2—0.5% | 2.4—0.5% | — | — | 0—0.0% | — | — | — | |
| Total liabilities | 53—15.3% | 53+38.7%15.3% | 54+558%14.2% | 45+514%10.9% | 37+90.4%8.3% | 38+575%7.9% | 8.1+45.5%4.1% | 7.4+33.3%3.8% | 20r5.7—11.9% | 5.6—2.9% | 5.6—2.9% | 5.5—3.0% | |
| Retained earnings | −489—−141% | −489—−141% | −455—−121% | −399—−95.5% | −357—−79.5% | −318—−65.5% | −7.3—−3.7% | −6.2—−3.1% | −223r−3.7—−135% | −3.5—−1.8% | −3.4—−1.8% | −3.2—−1.7% | |
| Shareholders' equity | 293—84.7% | 293−34.3%84.7% | 323—85.8% | 372—89.1% | 411—91.7% | 447—92.1% | −228r−7.3—−115% | −200r−6.2—−102% | −179r−3.7—−109% | −159r−3.5—−82.8% | −143r−3.4—−75.5% | −129r−3.2—−68.7% | |
| Total liabilities and equity | 346—100% | 346−28.6%100% | 377+90.8%100% | 418+113%100% | 448+173%100% | 485+152%100% | 197+4.0%100% | 196+4.3%100% | 164r194—100% | 192—100% | 190—100% | 188—100% | |
| Shares outstanding | 80—— | 80+1.3%— | 80—— | 80—— | 80+281412%— | 79—— | — | — | 0.0—— | — | — | — | |
| Cash-flow statement | |||||||||||||
| Share-based compensation | 19+602%— | 4.7+233%— | 7.2+19975%— | 3.9+517%— | 2.9*+402%— | 1.4+1741%— | 0.0−53.5%— | 0.6r0.1+1493%— | 0.6r0.1*—— | 0.1—— | 0.1—— | 0.0—— | |
| Cash from operating activities | −151—— | −28*—— | −44*—— | −36—— | −42*—— | −29r−71*—— | −23r−0.3*—— | −20r−0.7—— | −15r−0.1*—— | −39r−0.0*—— | −0.0*—— | −0.6—— | |
| Capital expenditure | −0.2—— | −0.0*—— | −0.0*—— | −0.0—— | −0.1*—— | −0.1*—— | −0.2*—— | −0.2—— | −0.0*—— | — | — | — | |
| Cash from investing activities | −182−299%— | 50*+24.1%— | 46*+374%— | −285−1957%— | 7.8*−69.6%— | 41*+7.0%— | 9.6*—— | 15—— | 26r0*—— | 38r0*—— | 0*—— | −184—— | |
| Shares issued | 104—— | 0*—— | 0*—— | 112—— | −8.6*—— | — | — | — | — | — | — | — | |
| Cash from financing activities | 0.2−100.0%— | 0.4*−99.9%— | 0.0*−99.8%— | 0.3—— | −0.6*−1227%— | 365*+1748%— | 19*—— | −0.4−100%— | 0.1r0*—— | 20r0*—— | 0*—— | 186—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at BridgeBio Oncology Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Auditor changedFiling
Auditor changed 1 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 8 · Material agreement 3 · Unregistered share sale 3 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 5
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Auditor changedChange in controlAcquisition or sale completedDirectors and officersMaterial agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersMaterial agreementUnregistered share saleBylaws or fiscal year changed | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
How BridgeBio Oncology Therapeutics, Inc. compares in Biotechnology
- Market cap$217 M · higher than 45% of 726
- Price / book0.5× · lower than 91% of 534
- FCF yield-52.8% · higher than 23% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc.🇺🇸 | $217 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at BridgeBio Oncology Therapeutics, Inc.? Verify and update this profile — free
Show BridgeBio Oncology Therapeutics, Inc.'s ranking on your website Get the badge
The badge updates itself as the ranking changes.